Acute cholangitis is a serious infection of the biliary tract that can lead to significant health complications. Symptoms typically include fever, abdominal pain (specifically in the upper right quadrant), and jaundice, which is known as Charcot’s triad. This patient is displaying all of these symptoms and has a history of gallstones, making acute cholangitis the most likely diagnosis. Treatment for acute cholangitis depends on the severity of the infection, as determined by the TG13 guideline. Patients will require intravenous fluids and antibiotics, and may need biliary drainage or intensive care support if the disease is severe. Influenza, acute cholecystitis, acute viral hepatitis, and biliary colic are all potential differential diagnoses, but do not match this patient’s symptoms and medical history.

Managing Crohn’s Disease: Guidelines and Treatment Options

Crohn’s disease is a type of inflammatory bowel disease that can affect any part of the digestive tract. To manage this condition, the National Institute for Health and Care Excellence (NICE) has published guidelines that provide recommendations for inducing and maintaining remission, as well as treating complications. One of the most important steps in managing Crohn’s disease is to advise patients to quit smoking, as this can worsen the condition. Additionally, some medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and the combined oral contraceptive pill, may increase the risk of relapse, although the evidence is not conclusive.

To induce remission, glucocorticoids are often used, either orally, topically, or intravenously. Budesonide is an alternative for some patients. Enteral feeding with an elemental diet may also be used, especially in young children or when there are concerns about the side effects of steroids. Second-line treatments for inducing remission include 5-ASA drugs like mesalazine, as well as azathioprine or mercaptopurine, which may be used in combination with other medications. Methotrexate is another option. Infliximab is useful for refractory disease and fistulating Crohn’s, and patients may continue on azathioprine or methotrexate.

To maintain remission, stopping smoking is a priority, and azathioprine or mercaptopurine is used first-line. TPMT activity should be assessed before starting these medications. Methotrexate is used second-line. Surgery may be necessary for around 80% of patients with Crohn’s disease, depending on the location and severity of the disease. Complications of Crohn’s disease include small bowel cancer, colorectal cancer, and osteoporosis. Perianal fistulae and abscesses require specific treatments, such as oral metronidazole, anti-TNF agents like infliximab, or a draining seton. By following these guidelines and treatment options, patients with Crohn’s disease can better manage their condition and improve their quality of life.

C. difficile infection (CDI) is caused by disruptions in the normal gut flora, which leads to increased colonization of C. difficile and the release of toxins that cause inflammation. Established risk factors for CDI include the use of antibiotics, protein pump inhibitors, antidepressants, and conditions that affect the immune system or decrease gastric acid secretion. Bowel and early emergency surgery have also been associated with higher rates of CDI, while there is no established link between CDI and extraintestinal surgery. GORD, T2DM, and lithium are not specifically linked to higher rates of CDI, but obesity, which can be linked to many conditions and medications, is a known risk factor. Interestingly, studies have shown that statins may have a protective effect against CDI, possibly through alterations in the microbiota or reduction of inflammation in endothelial cells.

Clostridioides difficile is a type of bacteria that is commonly found in hospitals. It is a Gram positive rod that produces an exotoxin which can cause damage to the intestines, leading to a condition called pseudomembranous colitis. This bacteria usually develops when the normal gut flora is suppressed by broad-spectrum antibiotics, with second and third generation cephalosporins being the leading cause of C. difficile. Other risk factors include proton pump inhibitors. Symptoms of C. difficile include diarrhea, abdominal pain, and a raised white blood cell count. The severity of the infection can be determined using the Public Health England severity scale, which ranges from mild to life-threatening.

To diagnose C. difficile, a stool sample is tested for the presence of C. difficile toxin (CDT). Treatment for a first episode of C. difficile infection typically involves oral vancomycin for 10 days, with fidaxomicin or a combination of oral vancomycin and IV metronidazole being used as second and third-line therapies. Recurrent infections occur in around 20% of patients, increasing to 50% after their second episode. In such cases, oral fidaxomicin is recommended within 12 weeks of symptom resolution, while oral vancomycin or fidaxomicin can be used after 12 weeks. For life-threatening C. difficile infections, oral vancomycin and IV metronidazole are used, and surgery may be considered with specialist advice. Other therapies, such as bezlotoxumab and fecal microbiota transplant, may also be considered for preventing recurrences in certain cases.

Management of Dyspepsia in Primary Care: Guidelines and Recommendations

Dyspepsia is a common complaint in primary care, encompassing a range of symptoms such as epigastric pain, heartburn, acid regurgitation, bloating, nausea, and vomiting. Here are some guidelines and recommendations for managing dyspepsia in primary care:

One-month trial of full-dose PPI: NICE guidelines recommend offering empirical full-dose PPI therapy for 4 weeks to patients with dyspepsia. Helicobacter pylori testing should also be offered, but a 2-week washout PPI-free period is necessary before testing.

Helicobater pylori stool test and routine referral for OGD: In young patients with no risk factors and relatively benign history and physical findings, routine referral for an endoscopy or testing for Barrett’s esophagus is not necessary.

Long-term low-dose PPI: If symptoms recur after initial treatment, offering a PPI at the lowest dose possible to control symptoms would be appropriate. H2 receptor antagonist therapy should be considered if there is an inadequate response to a PPI.

Refer urgently for OGD: Patients presenting with dyspepsia and significant acute GI bleeding should be referred for same-day assessment to a specialist. Other reasons for urgent referral would be the suspicion of malignancy, which in young patients with no red flag symptoms would be unwarranted.

Triple therapy for Helicobacter pylori eradication: Testing for Helicobacter pylori should be offered to patients with dyspepsia after a 2-week washout PPI-free period. It would be inappropriate to initiate triple therapy treatment without a positive test result first.

In summary, dyspepsia in the general population in primary care is defined broadly to include patients with recurrent epigastric pain, heartburn or acid regurgitation, with or without bloating, nausea, or vomiting. Management should follow evidence-based guidelines and recommendations to ensure appropriate and effective treatment.

Referral for Investigation of Colorectal Cancer with a 2-Week Wait

According to the National Institute for Health and Care Excellence (NICE) guidelines, patients aged 40 or over who present with unexplained weight loss and abdominal pain should be referred for investigation of colorectal cancer with a 2-week wait. Other criteria for a 2-week wait referral include patients with unexplained rectal bleeding, iron-deficiency anaemia, change in bowel habit, positive faecal occult blood tests, rectal or abdominal mass, unexplained anal mass or anal ulceration, and patients under 50 years with rectal bleeding and any of the following unexplained symptoms or findings: abdominal pain, change in bowel habit, weight loss or iron-deficiency anaemia.

Doing nothing and just following up with the patient, prescribing analgesia and following up in one month, referring the patient routinely, or taking urgent bloods and following up in two weeks would not be appropriate in the presence of red-flag symptoms and can create a serious delay in diagnosis and treatment. Therefore, referral for investigation of colorectal cancer with a 2-week wait is the recommended course of action. However, taking urgent bloods and following up the patient in two weeks can still be done while the patient is waiting for the referral appointment.